Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn MoreTargeted therapies offer advantages over conventional therapies in terms of selectivity, efficacy and tolerability. Small molecule drugs are a key component of the major targeted therapies used in the treatment of cancer. Alfa Cytology specializes in the development of customized small molecule drugs specifically for breast cancer.
Small molecule drugs can penetrate cell membranes to target intracellular proteins, and their stability and oral characteristics allow for direct and efficient drug delivery to patients. Compared with biological products, small molecule drugs' pharmacokinetic and pharmacodynamic properties are more predictable, so the corresponding drug treatment regimen is more straightforward. Small molecule drugs play an essential role in breast cancer (BC) therapy.
Fig.1 Molecular subtypes of breast cancer and types of triple-negative breast cancer. (Islam MR, et al., 2022)
Breast cancer is a heterogeneous disease, with various subtypes characterized by distinct genetic and molecular profiles. This diversity necessitates a tailored approach to drug development, where small molecules can be designed to target specific oncogenic pathways. For instance, inhibitors of the estrogen receptor (ER), such as tamoxifen and aromatase inhibitors, have become standard treatments for ER-positive breast cancer, significantly improving survival rates.
Target | Therapeutics | NCT | Phase |
Fibroblast Growth Factor Receptor (FGFR) inhibitors | Erdafitinib,fulvestrant,and palbociclib | NCT03238196 | |
Futibatinib | NCT02052778 | ||
RLY-4008 | NCT04526106 | ||
Angiopoietin inhibitors | Trebananib and standard therapies | NCT01042379 | |
Interleukin agonists | Efineptakin alfa and pembrolizumab | NCT04332653 | |
Pegilodecakin and anticancer drugs | NCT02009449 | ||
TGF-β/TGF-βR inhibitors | Bintrafusp alfa | NCT04489940 | |
SHR1701 and cyclin-dependent kinase 4/6 inhibitor | NCT04355858 | ||
NIS793 and anti-PD-1 antibody | NCT02947165 | ||
PF-06952229,palbociclib,and letrozole,or enzalutamide | NCT03685591 |
Alfa Cytology can provide you with BC small molecule drug development services. Our services include:
|
|
|
|
|
Method | Description |
---|---|
Virtual high-throughput screening | Using the mighty computing power of the computer, using the three-dimensional pharmacophore model or the method of molecular docking, it is a method to search for possible active compounds in the compound database. |
DNA-encoded small molecule compound library synthesis and screening technology | Utilizing the method of combinatorial chemistry and the diversity and expandability of DNA coding, it can quickly provide lead compounds for the early decisive stage of drug development, thereby speeding up the development process of new drugs. |
Alfa Cytology is driven by R&D and innovation, focusing on the development of small-molecule drugs. Our team is composed of highly educated and high-quality professionals with good professional backgrounds and experience in BC research. We have a complete set of technologies including small molecule screening, synthesis, drug analysis, stability research, and preparation development. If you are interested in learning more about our BC therapy development services, please feel free to contact us. Our professional and patient staff will get in touch with you as soon as possible.
Reference